Obstructive sleep apnoea (OSA) and non-alcoholic fatty liver disease (NAFLD) are two of many diseases associated with obesity. NAFLD is a common condition ranging in severity from liver steatosis to non-alcoholic steatohepatitis and liver fibrosis, the last step of NAFLD progression. Numerous studies have investigated whether the frequent co-occurrence of OSA and NAFLD simply reflects their link to obesity, or whether there is an independent pathophysiological interconnection between the two diseases (see [1] for comprehensive review). In animal models, intermittent hypoxia mimicking OSA has been shown to cause insulin resistance, dysfunction of key steps in hepatic lipid metabolism, liver steatosis and fibrosis [1]. In patients with OSA and metabolic comorbidities, liver steatosis measured by magnetic resonance imaging is associated with male sex and insulin resistance, but not with OSA severity and nocturnal hypoxia http://bit.ly/2kqyi3O

中文翻译：

---

磁共振成像测量阻塞性睡眠呼吸暂停严重程度和肝脂肪变性

阻塞性睡眠呼吸暂停 (OSA) 和非酒精性脂肪肝 (NAFLD) 是与肥胖相关的众多疾病中的两种。NAFLD 是一种常见疾病，严重程度从肝脂肪变性到非酒精性脂肪性肝炎和肝纤维化，这是 NAFLD 进展的最后一步。许多研究调查了 OSA 和 NAFLD 的频繁同时发生是否仅仅反映了它们与肥胖的联系，或者这两种疾病之间是否存在独立的病理生理学相互关联（综合综述见 [1]）。在动物模型中，模拟 OSA 的间歇性缺氧已被证明会导致胰岛素抵抗、肝脏脂质代谢关键步骤的功能障碍、肝脏脂肪变性和纤维化 [1]。在患有 OSA 和代谢合并症的患者中，